Novel approaches to therapeutic cancer vaccines

Expert Review of Vaccines

Volumn 2, Issue 4, 2003, Pages 517-532

  Hellstrom, Karl Erik ^a   Hellstrom, Ingegerd ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

4 1BB; CD137; CD83; Costimulation; Immunotherapy; scFv fragments; Tumor antigens; Tumor immunity

Indexed keywords

CANCER VACCINE; DNA VACCINE; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER; DENDRITIC CELL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

CANCER VACCINES; HUMANS; NEOPLASMS;

EID: 0041733079     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.4.517     Document Type: Review

References (166)

1. Hellstrom KE, Hellstrom I. Cellular immunity against tumor specific antigens. Adv. Cancer Res. 12, 167-223 (1969).
2. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T-cells. Immunol. Today 18, 267-268 (1997).
3. Pardoll DM. Cancer vaccines: a road map for the next decade. Curr. Opin. Immunol. 8, 619-621 (1996).
4. Steinman RM, Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109, 1519-1526 (2002).
5. Yee C, Greenberg PD. Monitoring T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat. Rev. Cancer 2, 409-419 (2002).
6. Hellstrom KE, Hellstrom I. Therapeutic vaccination with tumor cells that engage CD137. J. Mol. Med. 81, 71-86, (2003).
7. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T-cells, recurrence and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
8. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 411, 380-384 (2001).
9. Greenberg PD. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
10. Melief CJ, Kast WM. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T-lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145, 167-177 (1995).
11. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat. Med. 8, 343-348 (2002).
12. Reilly RT, Emens LA, Jaffee EM. Humoral and cellular immune responses; independent forces or collaborators in the fight against cancer. Curr. Opin. Investig. Drugs 2, 133-135 (2001).
13. Schwartz RH. Acquisition of immunologic self-tolerance. Cell 57, 1073-1081 (1989).
14. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T-cell responses to antigen. Ann. Rev. Immunol. 11, 191-212 (1993).
15. Thompson CB, Lindsten T, Ledbetter JA et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl Acad. Sci. USA 86, 1333-1337 (1989).
16. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T-lymphocyte molecules CD28 and CTLA-4. Cell 71, 1093-1102 (1992).
17. Yang G, Hellström KE, Hellström I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J. Immunol. 154, 2794-2800 (1995).
18. Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264, 961-965 (1994).
19. Yang G, Mizuno MT, Hellström KE, Chen L. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in lymph nodes. J. Immunol. 158, 851-85 (1997).
20. Ochsenbein AF, Sierro S, Odermatt B et al. Roles of tumour localization, second signal and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064, (2001).
21. Melero I, Singhal MC, McGowan P et al. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus Type 16. J. Virol. 71, 3998-4004 (1997).
22. Old LJ, Boyse EA. Immunology of experimental tumors. Ann. Rev. Med. 15, 167-186 (1964).
23. Clark EA, Ledbetter JA. How B- and T-cells talk to each other. Nature 367, 425-428 (1994).
24. + T-lymphocytes. J. Immunol. 152: 1523-1531 (1994).
25. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Ann. Rev. Immunol. 16, 111-135 (1998).
26. French RR, Chan HT, Tutt AL and Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548-553 (1999).
27. Diehl L, denBoer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy. Nat. Med. 5, 774-779 (1999).
28. Schoenberger SP, Jonges LE, Mooijaart RJ et al. Efficient direct priming of tumor-specific cytotoxic T-lymphocyte in vivo by an engineered APC. Cancer Res. 58, 3094-3100 (1998).
29. Todryk SM, Tutt AL, Green HA et al. CD40 ligation for immunotherapy of solid tumors. J. Immunol. Methods 248, 139-147 (2001).
30. Li Y, Hellström KE, Ashe Newby S, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183, 639-644 (1996).
31. Liu X, Bai XF, Wen J et al. B7H costimulates clonal expansion of and cognate destruction of tumor cells by, CD8(+) T-lymphocytes in vivo. J. Exp. Med. 194, 1339-1348 (2001).
32. Pardoll DM. Therapeutic vaccination for cancer. Clin. Immunol. 95, S44-S62 (2000).
33. Loetze MT, Hellerstedt B, Stolinski L et al. The role of interleukin-2, interleukin-12 and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3, (Suppl. 1), S109-S114 (1997).
34. Kiessling R, Wasserman K, Horiguchi S et al. Tumor-induced immune dysfunction. Cancer Immunol. Immunother. 48, 353-362 (1999).
35. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. defective antigen presentation in tumor-bearing hosts. Cellular Immunol. 170, 101-110 (1996).
36. Hellstrom I, Hellstrom KE. Tumor vaccines - a reality at last? J. Immunother. 21, 119-126 (1998).
37. Hellstrom KE, Hellstrom I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv. Immunol. 18, 209-277 (1974).
38. + T-cells by melanoma-derived altered peptide ligands, role of Melan-A/MART-1 optimized analogues. Cancer Res. 63, 1560-1567 (2003).
39. Gershon RK, Mokyr MB, Mitchell MS. Activation of suppressor T-cells by tumour cells and specific antibody. Nature 250, 594-596 (1974).
40. + regulatory T-cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3, 135-142 (2002).
41. + regulatory T-cells. Nat. Immunol. 4, 330-336 (2003).
42. Liyanage UK, Moore TT, Joo H-G et al. Prevalence of regulatory T-cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
43. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
44. Allison JP, Chambers C, Hurwitz A, Sullivan T, Boitel B, Fournier S, Brunner M, Krummel M. A role for CTLA-4-mediated inhibitory signals in peripheral T-cell tolerance? Novartis Found. Symp. 215, 92-98 (1998).
45. Egen JG, Kuhns MS, Allison JP. CTLA-4. new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
46. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand, implications for tumor immune escape. Science 274, 1363-1366 (1996).
47. Dong H, Strome SE, Salomao D et al. Tumor-associated By-H1 promotes T-cell apoptosis. A potential mechanism of immune-evasion. Nat. Med. 8, 793-800 (2002).
48. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-β) production by murine CD4(+) T-cells. J. Exp. Med. 188, 1849-1857 (1998).
49. + regulatory T-cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res. 62, 5267-5272 (2002).
50. Gorelik L, Flavell RA. Blockade of TGF-beta signaling in T-cells as a therapeutic modality in anticancer therapy. Scand J. Immunol. 54, 72 (2001).
51. Jager D, Jager F, Knuth A. Immune responses to tumour antigens. implications for antigen specific immunotherapy of cancer. J. Clin. Pathol. 54, 669-674 (2001).
52. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455-464 (2000).
53. Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L. Combined vaccination with major histocompatibility class I and interleukin-2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Cancer Res. 55, 4941-4949 (1995).
54. Wilson RE, Hager EB, Hampers CL, Corson JM, Merrill JP, Murray JE. Immunologic rejection of human cancer transplanted with a renal allograft. N. Engl. J. Med. 278, 479-483, 1968.
55. McSweeney PA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies. replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 97, 3390-3400 (2001).
56. Childs et al. Regression of metastatic renal cell carcinoma after nonmyeloablative allogeneic peripheral blood stem cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
57. Mihich E. Modulation of antitumor immune responses. Cancer Detect. Prev. (Suppl. 1), 399-407 (1987).
58. Emens LA, Machiels JP, Reilly RT, Jaffe EM. Chemotherapy. friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 3, 77-84 (2001).
59. Hellstrom KE, Hellstrom I, Kant JA, Tamerius JD. Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. J. Exp. Med. 148, 799-804 (1978).
60. Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. J. Exp. Med. 141, 697-702 (1975).
61. - T-cells. Tumor eradication does not require participation of cytotoxic T-cells. J. Exp. Med. 161, 1122-1134 (1985).
62. North RJ. Downregulation of the antitumor immune response. Adv. Cancer Res. 45, 1-43 (1985).
63. Boon T, Maryanski J. Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Cancer Surv. 4, 135-148 (1985).
64. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell Biol. 19, 7327-7335 (1999).
65. Daskalakis M, Nguyen TT, Nguyen C et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964 (2002).
66. Einhorn LH, Donohue JP. Advanced testicular cancer. update for urologists. J. Urol. 160, 1964-1969, (1998).
67. Aubry F, Satie AP, Rioux-Leclercq N et al. MAGE-A4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 92, 2778-2785 (2001).
68. Kendall A, Gilmore R, Newlands E. Chemotherapy for trophoblastic disease. current standards. Curr. Opin. Obstet. Gynecol. 14, 33-38 (2002).
69. Hellstrom I, Ledbetter JA, Scholler N et al. CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer. Proc. Natl Acad. Sci. USA 98, 6783-6788 (2001).
70. + cytolytic T-lymphocytes. J. Exp. Med. 183, 791-800 (1996).
71. Ovenvijk WW, Lee DS, Surman DR et al. Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice. Requirement for CD4(+) T-lymphocytes. Proc. Natl Acad. Sci. USA 96, 2982-2987 (1999).
72. Sjogren HO. Transplantation methods as a tool for detection of tumor specific antigens. Progress. Exp. Tumor Res. 6, 289-322 (1965).
73. Kallin B, Dillner J, Ernberg I et al. Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc. Natl Acad Sci. USA 83, 1499-1503 (1986).
74. Chen LP, Thomas EK, Hu SL, Hellström I, Hellström KE. Human papillomavirus Type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl Acad. Sci. USA 88, 110-114 (1991).
75. Ressing ME, Sette A, Brandt RM et al. Human CTL epitopes encoded by human papillomavirus Type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154, 5934-5943 (1995).
76. Malins DC, Polissar NL, Gunselman SJ. Progression of human breast cancers to the metastatic state is linked to hydroxyl radical-induced DNA damage. Proc. Natl Acad. Sci. 93, 2557-2563 (1996).
77. Klein G, Sjögren HO, Klein E, Hellström KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 20, 1561-1572 (1960).
78. Vaage J. Nonvirus-associated antigens in virus-induced mouse mammary tumors. Cancer Res. 28, 2477-2483 (1968).
79. Shiku H, Takahashi T, Oettgen HE. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J. Exp. Med 144, 873-881 (1976).
80. Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62, 5845-5852, (2002).
81. Shay JW, Wright WE. Telomerase, a target for cancer therapeutics. Cancer Cell 2, 257-265 (2002).
82. Su Z, Vierweg J, Weizer AZ et al. Enhanced induction of telomerase-specific CD4(+) T-cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res. 62, 5041-5048 (2002).
83. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 21, 674-679 (2002).
84. Schmidt SM, Schag K, Mueller MR et al. Survivin is a shared tumor associted antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T-cells. Blood (2003).
85. van der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8, 1019-1027 (2002).
86. Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T-lymphocytes in a human melanoma. Science 269, 1281-1284 (1995).
87. Bezieau LB, Benlalam H, Labarriere N, Guilloux Y, Diez I, Jotereau F. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J. Immunol. 168, 4802-4808, (2002).
88. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy 4, 317-327, (2002).
89. Disis ML, Gooley TA, Rinn K et al. Generation of T-cell immunity to the her-2/neu protein after active immunization with her-2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632 (2002).
90. Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res. 57, 1419-1424 (1997).
91. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens. an expanding family of targets for cancer immunotherapy. Immunol. Rev. 188, 22-32 (2002).
92. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes. identification, expression profile and putative function. J. Cell. Physiol. 194, 272-288 (2003).
93. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61, 5544-5551 (2001).
94. Kirkin AF, Dzhandzhugazyan KN, Zeuthen J. Cancer/testis antigens. structural and immunobiological properties. Cancer Invest. 20, 222-236 (2002).
95. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J. Exp. Med. 122, 467-481 (1965).
96. Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J. Vaccine thereapy of established tumors in the absence of autoimmunity. Clin. Cancer Res. 9, 1837-1849 (2003).
97. Finn OJ, Jerome KR, Henderson RA et al. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev. 145, 61-89 (1995).
98. Rosenberg SA. The identification of cancer antigens. impact on the development of cancer vaccines. Cancer J. Sci. Am. 6(Suppl. 2), S 142-S 149 (2000).
99. Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8, 1369-1375 (2002).
100. Bystryn JC, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61, 1065-1070 (1988).
101. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J. Clin. 46, 225-244 (1996).
102. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE. Tumor immunogenicity determines the effect of B7 costimulation on T-cell-mediated tumor immunity. J. Exp. Med. 179, 523-532 (1994).
103. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54, 6477-6483 (1994).
104. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T-cell activation. Immunity 1, 405-413 (1994).
105. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T-cells. J. Exp. Med. 183, 2533-2540 (1996).
106. Winberg G, Grosmaire LS, Klussman K, Hayden MS, Fell HP, Ledbetter JA, Mittler RS. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol. Rev. 153, 209-223 (1996).
107. Hayden MS, Gilliland LK, Ledbetter JA. Antibody engineering. Curr. Opin. Immunol. 9, 201-212 (1997).
108. Hayden MS, Grosmaire LS, Norris NA et al. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Antigens 48, 242-254 (1996).
109. Oh S, Hodge JW, Ahlers JD, Burke DS, Schlom J, Berzofsky JA. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170, 2523-2530 (2003).
110. Tsang KY, Zhu M, Even J, Gulley J, Arlen P, Schlom J. The infection of human dendritic cells with recombinant avipos vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T-cells. Cancer Res. 61, 7568-7576 (2001).
111. Kwon BS et al. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272, 14272-14276 (1997).
112. Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3, 682-685 (1997).
113. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand synergy with the CD28 co-stimulatory pathway. Eur. J. Immunol. 28, 1116-1121 (1998).
114. Chen SH, Pham-Nguyen KB, Martinet O et al. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2, 39-46 (2000).
115. Kärre K. Express yourself or die. peptides, MHC molecules and NK cells. Science 267, 978-979 (1995).
116. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Ann. Rev. Immunol. 18, 767 (2000).
117. Scholler N, Hayden-Ledbetter M, Hellstrom KE, Hellstrom I, Ledbetter JA. CD83 is a sialic acid-binding immunoglobin-like lectin (Siglec) adhesion receptor that binds monocytes and a subset of activated CD8+ cells. J. Immunol. 166, 3865-3872, (2001).
118. Scholler N, Hayden-Ledbetter M, Dahlin A, Hellstrom I, Hellstrom KE, Ledbetter JA. CD83 regulates the development of cellular immunity. J. Immunol. 168, 2599-2602 (2002).
119. Srivastava P. Roles of heat-shock proteins in innate and adoptive immunity. Nat. Rev. Immunol. 2, 185-194 (2002).
120. Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen S, Jefferies WA. TAP expression provides a general method for improving the recognitin of malignant cells in vivo. Nature Biotech 18, 515-520, (2000).
121. Armstrong TD, Jaffee EM. Cytokine modified tumor vaccines. Surg. Oncol. Clin. N. Am. 11, 681-696 (2002).
122. Tuting T, De Leo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or 'self' antigens induce antitumor immunity in vivo. Eur. J. Immunol. 27, 2702-2707 (1997).
123. Hashimoto W, Tanaka F, Robbins PD et al. Natural killer but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int. J. Cancer 103, 508-513 (2003).
124. Salgia R, Lynch T, Skarin A et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
125. Wallack MK, Bash J. Vaccinia oncosylates as melanoma vaccines. In: Cutaneous Melanoma. Balch CM (Ed.) Lippincott, PA, USA, 548-550 (1992).
126. Nabel GJ, Gordon D, Bishop DK et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Natl Acad. Sci. 93, 15388-15393 (1996).
127. Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu. A vaccine strategy for 'self' tumour antigens. Immunology 93, 192-199 (1998).
128. Geiger JD, Hutchinson RJ, Hohenkirk LF et al. Vaccination of pediatric solid tumor patients with tumor-lysate pulsed dendritic cells can expand specific T-cells and mediate tumor regression. Cancer Res. 61, 8513-8519 (2001).
129. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
130. Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J. Immunol. 168, 2393-2401 (2002).
131. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T-lymphocyte responses using dendritic cells transfected with messanger RNA amplification from tumor cells. Cancer Res. 60, 1028-1034 (2000).
132. Nakamura M, Iwahashi M, Nakamori M et al. Dendritic cells genetically engineered to simultaneously express endogeneous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic tumor immunity. Clin. Cancer Res. 8, 2742-2749 (2002).
133. Fields RC, Shimizu J, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl Acad. Sci. 95, 9482-9487 (1998).
134. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells. the near future. Int. J. Cancer 94, 459-473 (2001).
135. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328-332 (1998).
136. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med 4, 321-327 (1998).
137. Smithers M, O'Connell K, MacFadyen S et al. Clinical responsse after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particular antigen. Cancer Immunol. Immunother. 52, 41-52 (2003).
138. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune diseases induced by dendritic cell immunization against leukemia. Leukemia Res. 23, 549-557 (1999).
139. Coggin JH Jr. The implications of embryonic gene expression in neoplasia. Crit. Rev. Oncol. Hematol. 5, 37-55 (1986).
140. Hellstrom KE, Hellstrom I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145, 123-145 (1995).
141. Guo Y, Wu M, Chen HL et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B-cells. Science 263, 518-520 (1994).
142. Scheibenbogen C, Schadendorf D, Bechrakis NE et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer 104, 188-194 (2003).
143. Knutson KL, Schiffman K, Disis M-L. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484 (2001).
144. Machiels JP, van Baren N, Marchand M. Peptide-based cancer vaccines. Semin. Oncol. 29, 494-502 (2002).
145. Springer GF, Desai PR, Tegtmeyer H, Carlstedt SC, Scanlon EF. T/Tn antigen vaccine is effective and safe in preventing recurrence of advanced human breast carcinoma. Cancer Biother. 9, 7-15 (1994).
146. Wolchok JD, Livingston PO. Vaccines for melanoma, translating basic immunology into new therapies. Lancet Oncol. 2.205-211 (2001).
147. Kwak H, Horig H, Kaufman HL. Poxviruses as vectors for cancer immunotherapy. Curr. Opin. Drug Discov. Develop. 6, 161-168 (2003).
148. Estin CD, Stevenson US, Plowman GD et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc. Natl Acad. Sci. USA 85, 1052-1056 (1988).
149. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA. Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res. 55, 3598-3603 (1995).
150. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59, 676 (1999).
151. Scholl SM, Balloul JM, Le Goc G et al. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J. Immunother. 23, 570-580 (2000).
152. Paterson Y, Ikonomidis G. Recombinant Listeria monocytogenes cancer vaccines. Curr. Opin. Immunol. 8, 664-669 (1996).
153. Gunn GR, Zubair A, Peters C, Pan Z, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T-cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167, 6471-6479 (2001).
154. Kowalczyk DW, Ertl HC. Immune responses to DNA vaccines. Cell Mol. Life Sci. 55, 751-770 (1999).
155. Tuting T, Gambotto A, DeLeo A, Lotze MT, Robbins PD, Storkus WJ. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Ther. 6, 73-80 (1999).
156. Minion FC, Menon SA, Mahairas GG, Wannemuehler MJ. Enhanced murine antigen-specific γ interferon and immunoglobulin G2a responses by using mycobacterial ESAT-6 sequences in DNA vaccines. Infect. Immun. 71, 2239-2243 (2003).
157. Kamata M, Denda-Nagai K, Kubota N, Aida S, Takeda K, Irimura T. Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases. Clin. Exp. Metastasis 19, 689-696 (2002).
158. Steitz J, Bruck J, Gambotto A, Knop J, Tuting T. Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. Gene Ther. 9, 208-213 (2002).
159. Timmerman JM, Singh G, Hemanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62, 5845-5852 (2002).
160. Conry RM, Curiel DT, Strong TV, More SE, Allen KO, Barlow DL, Shaw DR, Lobuglio AF. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8, 2782-2787 (2002).
161. Menon SA, Wannemuehler MJ, Mahairas GG, Minion FC. Mycobacterial ESAT-6 protein enhances mouse IFN-gamma responses to Mycoplasma hyopneumoniae P71 protein. J. Interferon Cytokine Res. 22, 807-813 (2002).
162. Forstrom JW, Nelson KA, Nepom GT, Hellstrom I, Hellstrom KE. Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody. Nature 303, 627-629 (1983).
163. Koprowski H, Herlyn D, Lubeck M, DeFreitas E, Sears HF. Human anti-idiotype antibodies in cancer patients. Is the modulation of the immune response beneficial for the patient? Proc. Natl Acad. Sci. USA 81, 216-219 (1984).
164. Lee VK, Harriott TG, Kuchroo VK, Halliday WJ, Hellström I, Hellström KE. Monoclonal anti-idiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc. Natl Acad. Sci. USA 82, 6286-6290 (1985).
165. Birebent B, Mitchell E, Akis N et al. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral, cellular immune responses inn colorectal cancer patients. Vaccine 21, 1601-1612 (2003).
166. Basak S, Birebent B, Purev E et al. Induction of celllular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol. Immunother. 52, 145-154 (2003).